Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Meridian Research
809
mi
from
Columbus, GA
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Meridian Research
809
mi
from
Columbus, GA
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Medex Healthcare Research, Inc.
1284
mi
from
New York, NY
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Medex Healthcare Research, Inc.
1284
mi
from
New York, NY
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Om Medical
961
mi
from
Henderson, NV
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Om Medical
961
mi
from
Henderson, NV
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
MedEx Healthcare Research Inc
411
mi
from
St Louis, MO
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
MedEx Healthcare Research Inc
411
mi
from
St Louis, MO
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
New Hanover Medical Research
1136
mi
from
Wilmington, NC
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
New Hanover Medical Research
1136
mi
from
Wilmington, NC
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
PMG Research of WS
973
mi
from
Winston-Salem, NC
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
PMG Research of WS
973
mi
from
Winston-Salem, NC
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Medical Frontiers
738
mi
from
Carlisle, OH
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Medical Frontiers
738
mi
from
Carlisle, OH
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Ellipsis Research
973
mi
from
Columbia, SC
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Ellipsis Research
973
mi
from
Columbia, SC
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
PMG Research of Charleston
1066
mi
from
Mt. Pleasant, SC
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
PMG Research of Charleston
1066
mi
from
Mt. Pleasant, SC
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Mercury Clinical Research
563
mi
from
Houston, TX
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Mercury Clinical Research
563
mi
from
Houston, TX
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Quality Research
572
mi
from
San Antonio, TX
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Quality Research
572
mi
from
San Antonio, TX
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Highland Clinical Research
775
mi
from
Salt Lake City, UT
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Highland Clinical Research
775
mi
from
Salt Lake City, UT
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Strelitz Diabetes Center
1182
mi
from
Norfolk, VA
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
Phase II Study of Glycemic Control, Safety, Tolerability and Pharmacokinetic Parameters of TC-6987 Monotherapy in Subjects With Type 2 Diabetes Mellitus
Status: Archived
Updated: 1/1/1970
Strelitz Diabetes Center
1182
mi
from
Norfolk, VA
Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes
A Phase 1 Study in Patients With Type 1 Diabetes Mellitus to Evaluate the Single and Multiple Dose Pharmacokinetics and Safety of CBX129801 (Long-Acting Synthetic C-Peptide) After Subcutaneous Administration
Status: Archived
Clinical Trial Facility
1320
mi
from
Santa Clara, CA
Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes
A Phase 1 Study in Patients With Type 1 Diabetes Mellitus to Evaluate the Single and Multiple Dose Pharmacokinetics and Safety of CBX129801 (Long-Acting Synthetic C-Peptide) After Subcutaneous Administration
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1320
mi
from
Santa Clara, CA
Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes
A Phase 1 Study in Patients With Type 1 Diabetes Mellitus to Evaluate the Single and Multiple Dose Pharmacokinetics and Safety of CBX129801 (Long-Acting Synthetic C-Peptide) After Subcutaneous Administration
Status: Archived
Clinical Trial Facility
517
mi
from
Austin, TX
Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes
A Phase 1 Study in Patients With Type 1 Diabetes Mellitus to Evaluate the Single and Multiple Dose Pharmacokinetics and Safety of CBX129801 (Long-Acting Synthetic C-Peptide) After Subcutaneous Administration
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
517
mi
from
Austin, TX
Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes
A Phase 1 Study in Patients With Type 1 Diabetes Mellitus to Evaluate the Single and Multiple Dose Pharmacokinetics and Safety of CBX129801 (Long-Acting Synthetic C-Peptide) After Subcutaneous Administration
Status: Archived
Clinical Trial Facility
1413
mi
from
Mountlake Terrace, WA
Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes
A Phase 1 Study in Patients With Type 1 Diabetes Mellitus to Evaluate the Single and Multiple Dose Pharmacokinetics and Safety of CBX129801 (Long-Acting Synthetic C-Peptide) After Subcutaneous Administration
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1413
mi
from
Mountlake Terrace, WA
A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects
A Phase 1, Randomized, Open-Label, 3-Period, 3-Treatment, Single-dose Crossover Study to Evaluate the Pharmacokinetic Interaction of LX4211 and Metformin in Healthy Subjects
Status: Archived
Lexicon Investigational Site
572
mi
from
San Antonio, TX
A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects
A Phase 1, Randomized, Open-Label, 3-Period, 3-Treatment, Single-dose Crossover Study to Evaluate the Pharmacokinetic Interaction of LX4211 and Metformin in Healthy Subjects
Status: Archived
Updated: 1/1/1970
Lexicon Investigational Site
572
mi
from
San Antonio, TX
Duration of Infusion Set Function: Quick-Set Teflon Catheter Versus Sure-T Steel Infusion Set Catheter
Duration of Infusion Set Function: A Study Comparing the Quick-Set Teflon Catheter vs Sure-T Steel Infusion Set Catheter
Status: Archived
Stanford university Hospital and Clinics
1329
mi
from
Stanford, CA
Duration of Infusion Set Function: Quick-Set Teflon Catheter Versus Sure-T Steel Infusion Set Catheter
Duration of Infusion Set Function: A Study Comparing the Quick-Set Teflon Catheter vs Sure-T Steel Infusion Set Catheter
Status: Archived
Updated: 1/1/1970
Stanford university Hospital and Clinics
1329
mi
from
Stanford, CA
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
Status: Archived
Raleigh Regional Cancer Center
906
mi
from
Beckley, WV
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Raleigh Regional Cancer Center
906
mi
from
Beckley, WV
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
Status: Archived
Pfizer Investigational Site
572
mi
from
Houston, TX
Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
572
mi
from
Houston, TX
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
858
mi
from
Peoria, AZ
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
858
mi
from
Peoria, AZ
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
1320
mi
from
Santa Clara, CA
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1320
mi
from
Santa Clara, CA
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
1143
mi
from
Celebration, FL
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1143
mi
from
Celebration, FL
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
475
mi
from
Centralia, IL
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
475
mi
from
Centralia, IL
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
956
mi
from
Great Falls, MT
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
956
mi
from
Great Falls, MT
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
958
mi
from
Charlotte, NC
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
958
mi
from
Charlotte, NC
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
761
mi
from
Lima, OH
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
761
mi
from
Lima, OH
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
1063
mi
from
Charleston, SC
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1063
mi
from
Charleston, SC
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
517
mi
from
Austin, TX
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
517
mi
from
Austin, TX
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Clinical Trial Facility
790
mi
from
Ogden, UT
A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
790
mi
from
Ogden, UT
Randomized, Double-blind, Crossover, PK and GD Study of CSII in Subjects With Type 1 Diabetes
Randomized, Double-Blind, Pharmacokinetic (PK) and Glucodynamic (GD) Crossover Study of Continuous Subcutaneous Insulin Infusion (CSII) of Rapid Acting Insulin Analogs With and Without Recombinant Human Hyaluronidase (rHuPH20)
Status: Archived
Profil Institute for Clinical Research
1140
mi
from
Chula Vista, CA
Randomized, Double-blind, Crossover, PK and GD Study of CSII in Subjects With Type 1 Diabetes
Randomized, Double-Blind, Pharmacokinetic (PK) and Glucodynamic (GD) Crossover Study of Continuous Subcutaneous Insulin Infusion (CSII) of Rapid Acting Insulin Analogs With and Without Recombinant Human Hyaluronidase (rHuPH20)
Status: Archived
Updated: 1/1/1970
Profil Institute for Clinical Research
1140
mi
from
Chula Vista, CA
A Placebo-Controlled, Randomized, Safety and Efficacy Study to Evaluate the Change in Hemoglobin A1c Levels in Type 2 Diabetic Subjects While Taking Nutralin
A Phase II, Placebo-Controlled, Randomized, Safety and Efficacy Study to Evaluate the Change in Hemoglobin A1c Levels in Type 2 Diabetic Subjects While Taking Nutralin
Status: Archived
Avera Research Institute
402
mi
from
Sioux Falls, SD
A Placebo-Controlled, Randomized, Safety and Efficacy Study to Evaluate the Change in Hemoglobin A1c Levels in Type 2 Diabetic Subjects While Taking Nutralin
A Phase II, Placebo-Controlled, Randomized, Safety and Efficacy Study to Evaluate the Change in Hemoglobin A1c Levels in Type 2 Diabetic Subjects While Taking Nutralin
Status: Archived
Updated: 1/1/1970
Avera Research Institute
402
mi
from
Sioux Falls, SD
A Study Of PF-05175157 In Healthy Volunteers
A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-05175157 After Administration Of Single Escalating Oral Doses Under Fasted And Fed Conditions In Healthy Volunteers
Status: Archived
Raleigh Regional Cancer Center
906
mi
from
Beckley, WV
A Study Of PF-05175157 In Healthy Volunteers
A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-05175157 After Administration Of Single Escalating Oral Doses Under Fasted And Fed Conditions In Healthy Volunteers
Status: Archived
Updated: 1/1/1970
Raleigh Regional Cancer Center
906
mi
from
Beckley, WV
Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes
A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses Of PF-04937319 In Adult Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Raleigh Regional Cancer Center
906
mi
from
Beckley, WV
Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes
A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses Of PF-04937319 In Adult Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
Raleigh Regional Cancer Center
906
mi
from
Beckley, WV
Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes
A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses Of PF-04937319 In Adult Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Pfizer Investigational Site
896
mi
from
Akron, OH
Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes
A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses Of PF-04937319 In Adult Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
896
mi
from
Akron, OH
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Mesa Family Medical Center
839
mi
from
Mesa, AZ
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
Mesa Family Medical Center
839
mi
from
Mesa, AZ
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Clinical Research Advantage
836
mi
from
Mesa, AZ
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
Clinical Research Advantage
836
mi
from
Mesa, AZ
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Woodland International Reserach Group, LLC
372
mi
from
Little Rock, AR
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
Woodland International Reserach Group, LLC
372
mi
from
Little Rock, AR
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Associated Pharmaceutical Research
1159
mi
from
Buena Park, CA
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
Associated Pharmaceutical Research
1159
mi
from
Buena Park, CA
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
John Muir Clinical Research
1316
mi
from
Concord, CA
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
John Muir Clinical Research
1316
mi
from
Concord, CA
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
*Private Practice*
1161
mi
from
Pasadena, CA
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
*Private Practice*
1161
mi
from
Pasadena, CA
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Apex Research Institute
1152
mi
from
Santa Ana, CA
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
Apex Research Institute
1152
mi
from
Santa Ana, CA
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
California Neuropsychopharmacology Clinical Research Institute (CNRI)
1141
mi
from
San Diego, CA
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
California Neuropsychopharmacology Clinical Research Institute (CNRI)
1141
mi
from
San Diego, CA
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
California Research Foundation
1142
mi
from
San Diego, CA
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
California Research Foundation
1142
mi
from
San Diego, CA
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Orange County Research Center
1152
mi
from
Tustin, CA
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
Orange County Research Center
1152
mi
from
Tustin, CA
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Diablo Clinical
1319
mi
from
Walnut Creek, CA
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
Diablo Clinical
1319
mi
from
Walnut Creek, CA
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Veterans Affairs Medical Center - Dallas
353
mi
from
Dallas, TX
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
Veterans Affairs Medical Center - Dallas
353
mi
from
Dallas, TX
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Complete Family Care
413
mi
from
Northglenn, CO
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
Complete Family Care
413
mi
from
Northglenn, CO
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Research Center Phase 1-4 of Florida
1313
mi
from
Miami, FL
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
Research Center Phase 1-4 of Florida
1313
mi
from
Miami, FL
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Metabolic Research Institute, Inc.
1284
mi
from
West Palm Beach, FL
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
Status: Archived
Updated: 1/1/1970
Metabolic Research Institute, Inc.
1284
mi
from
West Palm Beach, FL